Literature DB >> 10072434

Mutations of OCTN2, an organic cation/carnitine transporter, lead to deficient cellular carnitine uptake in primary carnitine deficiency.

N L Tang1, V Ganapathy, X Wu, J Hui, P Seth, P M Yuen, R J Wanders, T F Fok, N M Hjelm.   

Abstract

Systemic primary carnitine deficiency (CDSP, OMIM 212140) is an autosomal recessive disease characterized by low serum and intracellular concentrations of carnitine. CDSP may present with acute metabolic derangement simulating Reye's syndrome within the first 2 years of life. After 3 years of age, patients with CDSP may present with cardiomyopathy and muscle weakness. A linkage with D5S436 in 5q was reported in a family. A recently cloned homologue of the organic cation transporter, OCTN2, which has sodium-dependent carnitine uptake properties, was also mapped to the same locus. We screened for mutation in OCTN2 in a confirmed CDSP family. One truncating mutation (Trp132Stop) and one missense mutation (Pro478Leu) of OCTN2 were identified together with two silent polymorphisms. Expression of the mutant cDNAs revealed virtually no uptake activity for both mutations. Our data indicate that mutations in OCTN2 are responsible for CDSP. Identification of the underlying gene in this disease will allow rapid detection of carriers and postnatal diagnosis of affected patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072434     DOI: 10.1093/hmg/8.4.655

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  24 in total

Review 1.  Role of plasma membrane transporters in muscle metabolism.

Authors:  A Zorzano; C Fandos; M Palacín
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

Review 2.  Carnitine biosynthesis in mammals.

Authors:  Frédéric M Vaz; Ronald J A Wanders
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

3.  Identification of mutations and evaluation of cardiomyopathy in Turkish patients with primary carnitine deficiency.

Authors:  M Kilic; R K Ozgül; T Coşkun; D Yücel; M Karaca; H S Sivri; A Tokatli; M Sahin; T Karagöz; A Dursun
Journal:  JIMD Rep       Date:  2011-09-22

4.  Importance of molecular diagnosis in the accurate diagnosis of systemic carnitine deficiency.

Authors:  Toshiaki Hitomi; Norio Matsuura; Yosuke Shigematsu; Yoshiyuki Okano; Eri Shinozaki; Masahiko Kawai; Hatasu Kobayashi; Kouji H Harada; Akio Koizumi
Journal:  J Genet       Date:  2015-03       Impact factor: 1.166

5.  Identification of two novel mutations in OCTN2 from two Saudi patients with systemic carnitine deficiency.

Authors:  Z Rahbeeni; F M Vaz; K Al-Hussein; M P Bucknall; J Ruiter; R J Wanders; M S Rashed
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

Review 6.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

7.  SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE).

Authors:  Chunyu Wang; Ivan P Uray; Abhijit Mazumdar; Julie Ann Mayer; Powel H Brown
Journal:  Breast Cancer Res Treat       Date:  2012-01-03       Impact factor: 4.872

8.  Functional and molecular studies in primary carnitine deficiency.

Authors:  Marta Frigeni; Bijina Balakrishnan; Xue Yin; Fernanda R O Calderon; Rong Mao; Marzia Pasquali; Nicola Longo
Journal:  Hum Mutat       Date:  2017-09-14       Impact factor: 4.878

Review 9.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

10.  Role of carnitine in disease.

Authors:  Judith L Flanagan; Peter A Simmons; Joseph Vehige; Mark Dp Willcox; Qian Garrett
Journal:  Nutr Metab (Lond)       Date:  2010-04-16       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.